<DOC>
	<DOCNO>NCT00121914</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) consequence liver cirrhosis . In early tumour stage , tumour resection liver transplantation therapeutic option ; later tumour stage may treat locally ablative treatment percutaneous ethanol instillation ( PEI ) , transarterial chemoembolization ( TACE ) radio-frequency thermoablation . This randomized study investigates effect PEI survival patient HCC . All patient receive hormonal treatment ( long-acting somatostatin intramuscularly [ i.m . ] ) randomize treatment PEI additional treatment .</brief_summary>
	<brief_title>Treatment Hepatocellular Carcinoma : Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation ( PEI ) Versus Long-Acting Somatostatin Alone</brief_title>
	<detailed_description>This randomize two-arm parallel group study . - Study group : PEI + long-acting somatostatin - Control group : long-acting somatostatin alone Aims study : - Does treatment PEI+ long-acting somatostatin prolong survival compare treatment long-acting somatostatin alone ? - Can time tumour progression extend patient treat PEI + long-acting somatostatin compare treatment long-acting somatostatin alone ?</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Histologicallyproven hepatocellular carcinoma Treatable percutaneous ethanol instillation Inoperable tumour Age 1885 year Liver cirrhosis Child C Tumour diameter &gt; 8 cm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Carcinoma , Hepatocellular ,</keyword>
	<keyword>percutaneous ethanol instillation</keyword>
	<keyword>long-acting somatostatin</keyword>
</DOC>